Skip to search formSkip to main contentSkip to account menu

BSF 208075

Known as: (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic Acid, BSF-208075, BSF208075 
National Institutes of Health

Related topics

Related topics

2 relations
LU 208075

Broader (1)

ambrisentan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils
2004
2004
Endothelin receptor antagonists are not beneficial in the therapy of acute experimental pancreatitis
Background and aimDue to increased capillary permeability and the early appearance of vasoactive and toxic agents, patients… 
2002
2002
Left But Not Right Cardiac Hypertrophy in Atrial Natriuretic Peptide Receptor–Deficient Mice Is Prevented by Angiotensin Type 1 Receptor Antagonist Losartan
Mice with a genetic deletion of the atrial natriuretic peptide (ANP) receptor, guanylyl cyclase A (GC-A −/−), have chronic… 
Review
2002
Review
2002
Ambrisentan (Myogen).
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)